Perseus Proteomics, Inc. 4882

TSE · Japan · Health Technology

¥161.00-5.00 (-3.01%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Perseus Proteomics, Inc. 4882

TSE · Japan · Health Technology

¥161.00-5.00 (-3.01%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-26.48% · 6MFull-screen chart

Open ¥163.00High ¥164.00Low ¥160.00Close ¥161.00Volume 135.40K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: ¥166.00
Day range: ¥160.00 – ¥164.00
52-week range: ¥134.00 – ¥340.00
Volume: 135.40K
Market cap: ¥3.06B
Next earnings date: 2026-11-12
Avg. volume (1Y): 569.94K

Performance

1 week

-5.85%

1 month

+13.38%

3 months

+1.26%

6 months

-28.76%

Year to date

-29.39%

1 year

-48.06%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Japan
Exchange: TSE
Shares outstanding: 18.43M
Employees: 35
ISIN: JP3836800007
Beta: 0.23

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 22, 2026

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Pharmaceuticals and Ono Pharmaceutical (sapablursen), Silence Therapeutics (Divesiran (SLN124)), Perseus Proteomics (PPMX-T003), Disc Medicines (DISC-3405), and others are evaluating their lead candidates in different stages of clinical development, respectively.New York, USA, April 22, 2026 (GLOB

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.